These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 2465816

  • 1. Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer.
    Matzkin H, Lewyshon O, Ayalon D, Braf Z.
    Cancer; 1989 Apr 01; 63(7):1287-91. PubMed ID: 2465816
    [Abstract] [Full Text] [Related]

  • 2. Use of gonadotropin-releasing hormone analogue in advanced prostatic cancer: 3 years clinical experience.
    Matzkin H, Greenstein A, Kaver I, Braf Z.
    Isr J Med Sci; 1989 Jul 01; 25(7):388-92. PubMed ID: 2474522
    [Abstract] [Full Text] [Related]

  • 3. Prostate-specific antigen. Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker.
    Dundas GS, Porter AT, Venner PM.
    Cancer; 1990 Jul 01; 66(1):45-8. PubMed ID: 1693877
    [Abstract] [Full Text] [Related]

  • 4. Comparison of prostate-specific antigen and prostatic acid phosphatase in the management of prostatic cancer.
    Turkes A, Nott J, Turkes AO, Griffiths K.
    Am J Clin Oncol; 1988 Jul 01; 11 Suppl 2():S77-9. PubMed ID: 2468280
    [Abstract] [Full Text] [Related]

  • 5. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
    Matzkin H, Eber P, Todd B, van der Zwaag R, Soloway MS.
    Cancer; 1992 Nov 01; 70(9):2302-9. PubMed ID: 1382828
    [Abstract] [Full Text] [Related]

  • 6. Value of biochemical markers in the management of disseminated prostatic cancer.
    Mulders PF, Fernandez del Moral P, Theeuwes AG, Oosterhof GO, van Berkel HT, Debruyne FM.
    Eur Urol; 1992 Nov 01; 21(1):2-5. PubMed ID: 1376692
    [Abstract] [Full Text] [Related]

  • 7. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
    Csapo Z, Brand K, Walther R, Fokas K.
    J Urol; 1988 Nov 01; 140(5):1032-8. PubMed ID: 2459419
    [Abstract] [Full Text] [Related]

  • 8. [Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].
    Petrone U, Gaspari G, Marascia G, Magnocavallo N, Petrone D, Tucci C.
    Minerva Urol Nefrol; 1990 Nov 01; 42(2):73-5. PubMed ID: 1697431
    [Abstract] [Full Text] [Related]

  • 9. Prostate tumour markers as an aid in the staging of prostatic cancer.
    Haapiainen RK, Permi EJ, Rannikko SA, Voutilainen PE, Liewendahl K, Stenman UH, Alfthan OS.
    Br J Urol; 1990 Mar 01; 65(3):264-7. PubMed ID: 1692497
    [Abstract] [Full Text] [Related]

  • 10. Immunologically measured serum markers and their role in the management of prostate cancer.
    Powell P, Neal D, Gibb I, Wilson L, Hall R.
    Eur Urol; 1988 Mar 01; 15(1-2):48-53. PubMed ID: 2463921
    [Abstract] [Full Text] [Related]

  • 11. Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer.
    Mannini D, Maver P, Aiello E, Corrado G, Vecchi F, Bellanova B, Marengo M.
    Urol Res; 1988 Mar 01; 16(1):9-12. PubMed ID: 2449758
    [Abstract] [Full Text] [Related]

  • 12. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X, Molina R, Jo J, Umbert B, Bedini JL, Ballesta AM.
    Tumour Biol; 1990 Mar 01; 11(6):289-94. PubMed ID: 1700860
    [Abstract] [Full Text] [Related]

  • 13. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
    Morote Robles J, de Torres Mateos JA.
    Arch Esp Urol; 1989 Mar 01; 42 Suppl 2():124-30. PubMed ID: 2484148
    [Abstract] [Full Text] [Related]

  • 14. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
    Tarle M.
    Anticancer Res; 1988 Mar 01; 8(4):569-72. PubMed ID: 2460018
    [Abstract] [Full Text] [Related]

  • 15. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
    Huhtaniemi I, Nikula H, Rannikko S.
    J Clin Endocrinol Metab; 1985 Oct 01; 61(4):698-704. PubMed ID: 2993345
    [Abstract] [Full Text] [Related]

  • 16. [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein].
    Shinoda I.
    Nihon Gan Chiryo Gakkai Shi; 1990 Nov 20; 25(11):2627-39. PubMed ID: 1703555
    [Abstract] [Full Text] [Related]

  • 17. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone.
    Waxman JH, Wass JA, Hendry WF, Whitfield HN, Bary P, Besser GM, Malpas JS, Oliver RT.
    Br J Urol; 1983 Dec 20; 55(6):737-42. PubMed ID: 6418264
    [Abstract] [Full Text] [Related]

  • 18. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
    Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E.
    N Engl J Med; 1987 Oct 08; 317(15):909-16. PubMed ID: 2442609
    [Abstract] [Full Text] [Related]

  • 19. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
    Théodon P, Rymer JC, Chopin D, Kouyoudjian JC, Abbou CC, Auvert J.
    Ann Urol (Paris); 1988 Oct 08; 22(3):199-205. PubMed ID: 2456713
    [Abstract] [Full Text] [Related]

  • 20. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
    Waxman JH, Wass JA, Hendry WF, Whitfield HN, Besser GM, Malpas JS, Oliver RT.
    Br Med J (Clin Res Ed); 1983 Apr 23; 286(6374):1309-12. PubMed ID: 6404441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.